The FDA recently approved Idaho Technology's Joint Biological Agent Identification and Diagnostic System (JBAIDS) for use as an aid in the diagnosis of anthrax.
The JBAIDS system can detect the gene components of anthrax (Bacillus anthracis) in a variety of environmental sample types, clinical blood samples and cultured organisms. The FDA clearance allows testing of blood and laboratory culture samples to aid in the laboratory identification of B. anthracis, with results in less than one hour. The current method of growing, isolating and identifying a culture can take as long as several days for results.
The JBAIDS was selected by the U.S. Department of Defense as the platform for use in rapid identification of over ten deadly pathogens associated with bioterrorism and diseases of military interest. "This is a great example of how private industry and the government can work as partners to protect our nation and those who defend it," said Todd Ritter, Idaho Technology's Chief Corporate Development Officer.